Big interest in heavy drugs

@article{Sanderson2009BigII,
  title={Big interest in heavy drugs},
  author={K. Sanderson},
  journal={Nature},
  year={2009},
  volume={458},
  pages={269-269}
}
Pharmaceutical companies are beginning to bet on the idea that simply switching a hydrogen atom with a heavier isotope in a currently approved drug could create a better drug. Encouraged by results from clinical trials, companies are snapping up intellectualproperty rights on many of the modified drugs. On 16 March, for example, Concert Pharmaceuticals of Lexington, Massachusetts, reported results of a phase I clinical trial for a version of the antidepressant paroxetine, sold as Seroxat by… Expand
Deuterated therapeutics: forensic toxicology consequences.
  • S. Kerrigan
  • Medicine, Chemistry
  • Journal of analytical toxicology
  • 2009
The toxicology community should be aware that pharmaceutical companies are developing deuterated analogues of therapeutic agents, purported to have improved margins of safety and reduced potentialExpand
Deuterated drugs: where are we now?
  • G. Timmins
  • Chemistry, Medicine
  • Expert opinion on therapeutic patents
  • 2014
TLDR
It would seem that the likelihood of obviousness rejections is increasing in this area, however, careful elucidation of metabolic outcomes from deuteration that would not be anticipated from the prior art, and are instead unexpected and unobvious, has enabled allowance. Expand
Applications in Medicinal Chemistry
Many studies have been conducted with heavy water to test the biological effects on the plants and animals. It was Professor Gilbert N. Lewis who conducted in 1933 the very first experiment onExpand
Drug Repurposing: Far Beyond New Targets for Old Drugs
TLDR
This approach is of interest primarily because the authors continue to face significant gaps in the drug–target interactions matrix and to accumulate safety and efficacy data during clinical studies. Expand
Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies.
TLDR
The activities of Isotope Chemistry at AstraZeneca is described and a brief overview of different commonly used approaches for the preparation of (14)C- and (3)H-labeled drug candidates are presented with in-house examples where relevant. Expand
Synopsis of some recent tactical application of bioisosteres in drug design.
  • N. Meanwell
  • Chemistry, Medicine
  • Journal of medicinal chemistry
  • 2011
TLDR
In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compound optimization and the long-term success of drug candidates. Expand
Effect of deuteration on metabolism and clearance of Nerispirdine (HP184) and AVE5638.
TLDR
Examination of the metabolic behaviour of two molecules from the Sanofi portfolio in a range of in vitro and in vivo systems indicates that it could be of value to concentrate efforts in this area to molecules which are metabolised by a major pathway that involves enzymes of the amine oxidase family or other low-capacity enzyme families. Expand
A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y12 Receptor
TLDR
CN-218 may be a promising antithrombotic agent, with potent antiplatelet and significant anticoagulant activity, as well as a lower risk of bleeding compared to clopidogrel and prasugrel. Expand
Deuterium-L-DOPA: a Novel Means to Improve Treatment of Parkinson's Disease
L-DOPA, the precursor of dopamine, is administered to restore dopamine deficiency in Parkinson s disease (PD) patients. L-DOPA initially provides a sustained symptomatic relief with superior efficacyExpand
Study on antiplatelet effect of a new thiophenopyridine platelets P2Y12 receptor antagonist DV-127.
TLDR
DV-127 was synthesized by using three generations of thienopyridine P2Y12 receptor antagonists as research models, using high resolution mass spectrometry, selective deuteration, and 2,7-position replacement groups technologies in order to maximize cardiovascular benefit while minimizing adverse effects on hemostasis and results show that although the dose of DV-127 is greatly reduced, it can achieve similar anticoagulant and antiplatelet effects as clopidogrel. Expand
...
1
2
3
4
5
...